Cellectis Announces FDA Grants Orphan Drug Designation To CLLS52 (Alemtuzumab) For Lymphodepletion Regimen In UCART22, Evaluated In BALLI-01 Clinical Trial For Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
Author: Benzinga Newsdesk | August 01, 2024 05:03pm